Evidence map›Paper›PMID 33488574›Full record

Observational studyFrontiers in immunology2020

Significant and Conflicting Correlation of IL-9 With

Elena Niccolai, Edda Russo, Simone Baldi, Federica Ricci, Giulia Nannini, Matteo Pedone, Francesco Claudio Stingo, Antonio Taddei, Maria Novella Ringressi, Paolo Bechi and 8 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Oral microbes and gastrointestinal cancers: new strategies and insights.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Elena NiccolaiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Edda RussoDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Simone BaldiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Federica RicciDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio" University of Florence, Florence, Italy.
Giulia NanniniDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Matteo PedoneDepartment of Statistics, Computer Science, Applications "G. Parenti", Florence, Italy.
Francesco Claudio StingoDepartment of Statistics, Computer Science, Applications "G. Parenti", Florence, Italy.
Antonio TaddeiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Maria Novella RingressiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Paolo BechiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Alessio MengoniDepartment of Biology, University of Florence, Florence, Italy.
Renato FaniDepartment of Biology, University of Florence, Florence, Italy.
Giovanni BacciDepartment of Biology, University of Florence, Florence, Italy.
Camilla FagorziDepartment of Biology, University of Florence, Florence, Italy.
Carolina ChielliniDepartment of Biology, University of Florence, Florence, Italy.
Domenico PriscoDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Matteo RamazzottiDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio" University of Florence, Florence, Italy.
Amedeo AmedeiDepartment of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Gut microbiota (GM) can support colorectal cancer (CRC) progression by modulating immune responses through the production of both immunostimulatory and/or immunosuppressive cytokines. The role of IL-9 is paradigmatic because it can either promote tumor progression in hematological malignancies or inhibit tumorigenesis in solid cancers. Therefore, we investigate the microbiota-immunity axis in healthy and tumor mucosa, focusing on the correlation between cytokine profile and GM signature. Methods: In this observational study, we collected tumor (CRC) and healthy (CRC-S) mucosa samples from 45 CRC patients, who were undergoing surgery in 2018 at the Careggi University Hospital (Florence, Italy). First, we characterized the tissue infiltrating lymphocyte subset profile and the GM composition. Subsequently, we evaluated the CRC and CRC-S molecular inflammatory response and correlated this profile with GM composition, using Dirichlet multinomial regression. Results: CRC samples displayed higher percentages of Th17, Th2, and Tregs. Moreover, CRC tissues showed significantly higher levels of MIP-1α, IL-1α, IL-1β, IL-2, IP-10, IL-6, IL-8, IL-17A, IFN-γ, TNF-α, MCP-1, P-selectin, and IL-9. Compared to CRC-S, CRC samples also showed significantly higher levels of the following genera: Conclusions: Our data consolidate antitumor immunity impairment and the presence of a distinct microbiota profile in the tumor microenvironment compared with the healthy mucosa counterpart. Relating the CRC cytokine profile with GM composition, we confirm the presence of bidirectional crosstalk between the immune response and the host's commensal microorganisms. Indeed, we document, for the first time, that

Indexed as

Gastrointestinal MicrobiomeAdenocarcinomaAdultAgedAged, 80 and overBacteroidesCase-Control StudiesColorectal NeoplasmsFemaleHumansInterleukin-9Intestinal MucosaLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrevotellaIL9 protein, humanInterleukin-9colorectal cancercytokinesgut microbiotaimmune responseT cells

Identifiers

PMID33488574
PMCPMC7820867
OpenAlexW3119059504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.